Clinical Trial

Physical Activity-based Intervention in Depressed Patients: Clinical, Neurophysiological, Epigenetic and Metabolic Correlates

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 25, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to investigate the effect of a structured physical activity (PA) program on depressive symptomatology in adults with a diagnosis of major depression disorder (MDD). The study will evaluate changes in depressive symptoms and assess neurophysiological and biological modulations, including epigenetic, transcriptomic, and metabolic changes resulting from the PA intervention. The main questions it aims to answer are: * Does physical activity have an impact on depressive symptoms in patients affected by depression? * What are the neurophysiological, epigenetic, and metabolic mechanisms through which PA can modulate the intensity of depressive symptoms? Participants will be randomized into two arms: the intervention group (n total=55), in treatment with antidepressants, participating in a 12-weeks PA program; the control group (n total=55), patients in treatment with antidepressants, without receiving the PA program. All participants will be assessed at three-time points: T0 (baseline, before initiating the trial), T3 (after three months; at the end of the 12-week PA program), and T6 (6th-month follow up; three months after the PA completion). At each assessment, all participants will: * Complete clinical evaluation questionnaires * Provide blood samples * Undergo electroencephalogram (EEG) measurements. * Wear an actigraph 24 hours a day for 7 days before the initiation of the trial, at T3, and at T6.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-19; most recent amendment 2026-03-24.
Status change: Recruiting → Active, Not Recruiting 2026-03-24
Trial Details
NCT Number NCT06989944
Lead Sponsor IRCCS Centro San Giovanni di Dio Fatebenefratelli
Collaborators: IRCCS San Raffaele, Istituto Neurologico Mediterraneo Neuromed S. R. L, Azienda Sanitaria Locale di Pescara
Conditions Major Depressive Disorder (MDD)
Enrollment 110 participants
Start Date 2025-05-01
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-25